
Pharvaris plans to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the first half of 2026 for the on-demand treatment of acute attacks of HAE.
Bullish
Pharvaris's deucrictibant demonstrated strong efficacy and safety in pivotal HAE trials, with plans for NDA submission in 2026. The company is expanding indications and leveraging its intellectual property and experienced team for future growth.
Bearish
Pharvaris faces significant financial challenges with ongoing losses and dependence on future funding. Clinical trial setbacks and intense competition, coupled with regulatory and pricing uncertainties, pose substantial risks to commercial success.